CoChat

Targeting the HIF2–VEGF axis in renal cell carcinoma

Choueiri, Toni K., Kaelin, William G. · 2020 · Nature Medicine

The DOI matches its Crossref record; 177 of the 179 references it cites were found in a registry or an index.

Abstract

Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as VEGF, for the treatment of cancers caused by VHL inactivation, such as clear-cell renal cell carcinoma (ccRCC). Multiple VEGF inhibitors are now approved for the treatment of ccRCC, and a HIF2α inhibitor has advanced to phase 3 development for this disease. These inhibitors are now also increasingly combined with immune-checkpoint blockers. In this Perspective, we describe the understanding of the mechanisms of oxygen sensing and hypoxia signaling that resulted in the development of HIF2α-targeted therapies for patients with VHL-associated tumors. We also present future directions for extending the use of these therapies to other cancers.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-020-1093-z

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 177 references

Research works printed but not linked: 3

  1. Choueiri, T. et al. Randomised phase 2 study of sapanisertib (TAK 228/MLN0128) ± TAK-117 versus everolimus in patients with VEGF-targeted therapy-refractory metastatic clear cell renal cell carcinoma. Fourteenth European International Kidney Cancer Symposium (2019).
  2. Mohlin, S., von Stedingk, K., Pietras, A. & Påhlman, S. No reason to reconsider HIF-2 as an oncogene in neuroblastoma and other cancer forms. Proc. Natl Acad. Sci. USA 114, E10856–E10858 (2017). · DOI
  3. Motzer, R. J. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1482 (2015). · DOI · Paper page

Cited by

See all 529

Metadata

Authors
Choueiri, T. K., & Kaelin, W. G.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
  • Choueiri, Toni K.
  • Kaelin, William G.
Venue
Nature Medicine
Published
2020-10-01
Volume
26
Issue
10
Pages
1519-1530
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3089803871
Cited by
477
References
179
Citations by year
2026: 60 · 2025: 68 · 2024: 83 · 2023: 93 · 2022: 100 · 2021: 72 · 2020: 1
FWCI
6.85
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Howard Hughes Medical Institute
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
HIF-2α, vascular endothelial growth factor, clear cell renal cell carcinoma, VHL, oxygen sensing, hypoxia signaling, VEGF inhibitors, immune checkpoint inhibitors, combination therapy
MeSH terms
Tumor Hypoxia, Endothelial PAS Domain-Containing Protein 1, Antineoplastic Agents, Carcinoma, Renal Cell, Humans, Kidney Neoplasms, Oxygen, Signal Transduction, Gene Expression Regulation, Neoplastic, Cell Respiration, Vascular Endothelial Growth Factor A, Basic Helix-Loop-Helix Proteins, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the HIF2–VEGF axis in renal cell carcinoma. https://app.cochat.ai/papers/10.1038/s41591-020-1093-z
The paper
Choueiri, T. K., & Kaelin, W. G. (2020). Targeting the HIF2–VEGF axis in renal cell carcinoma. Nature Medicine. https://doi.org/10.1038/s41591-020-1093-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.